Industry News

• Phase 1 data published in Nature Communications show potential of mRNA encoding VEGF-A  Moderna announced publication of a Phase 1a/b study in Nature Communications showing the potential of mRNA encoding for vascular endothelial growth factor A (VEGF-A) as a regenerative therapeutic. This approach aims to stimulate the growth of new blood vessels to improve blood flow in tissues.
  February 20, 2019  
• Leronlimab reduces by more than 98% human breast cancer metastasis in mouse xenografts  CytoDyn announces it was able to reduce by more than 98% the incidence of human breast cancer metastasis in a mouse xenograft model for cancer through six weeks with leronlimab (PRO 140). Based on these results, CytoDyn announced plans for expansion of pre-clinical animal studies.
  February 20, 2019  
• Achaogen announces closing of $15 million underwritten public offering  Achaogen announced the completion of its underwritten public offering of 15,000,000 shares of its common stock and accompanying short-term warrants to purchase up to 15,000,000 shares of its common stock and long-term warrants to purchase up to 15,000,000 shares of its common stock.
  February 20, 2019  
• Diet drink consumption linked to higher stroke and heart disease in post-menopausal women  A study led by Albert Einstein College researchers found a link between daily consumption of multiple diet drinks and higher stroke risk among post-menopausal women. The association was stronger in obese women and African-American women. The study was published in Stroke, a journal of the AMA.
  February 20, 2019  
• Five Prime Therapeutics doses first patient in phase 1b trial of FPA150  Five Prime Therapeutics announced that it initiated patient dosing in the Phase 1b dose expansion portion of the Phase 1a/1b clinical trial of FPA150 (FPA150-001; NCT03514121), a first-in-class immuno-oncology antibody that targets B7-H4.
  February 20, 2019  
• DelMar Pharma achieves halfway enrollment point for phase 2 clinical trial of VAL-083  DelMar Pharma announced its Phase 2 study testing VAL-083 in patients with newly diagnosed glioblastoma multiforme has achieved its halfway enrollment point. This trial is a single-arm, open-label study testing VAL-083 in combination with standard radiotherapy.
  February 20, 2019  
• Recro Pharma announces new IV meloxicam data publication  Recro Pharma announced the publication of new intravenous meloxicam data. The article, titled “Meloxicam intravenous for the treatment of moderate to severe acute pain: a pooled analysis of safety and opioid-reducing effects,” was published in Regional Anesthesia & Pain Medicine.
  February 20, 2019  
• Scientists identify unique subtype of eczema linked to food allergy  Scientists have now found that children with both atopic dermatitis and food allergy have structural and molecular differences in the top layers of healthy-looking skin near the eczema lesions, according to research published in Science Translational Medicine.
  February 20, 2019  
• Reata announces positive phase 2 data for bardoxolone methyl in patients with FSGS  Reata announced positive, final results from the focal segmental glomerulosclerosis cohort of PHOENIX, a Phase 2 study of bardoxolone methyl (bardoxolone) in patients with rare forms of CKD. Compared to baseline, bardoxolone significantly improved kidney function the primary endpoint.
  February 20, 2019  
• Nitisinone increases melanin in people with albinism  A small pilot clinical study at the NEI suggests the drug nitisinone increases melanin production in some people with oculocutaneous albinism type 1B (OCA-1B), a rare genetic disease that causes pale skin and hair and poor vision. Study results were published in JCI Insight.
  February 20, 2019  

   (next 10 articles)